Skip to main content
SpringerLink
Log in

Effect of Chinese Medicine on No or Slow Reflow after Percutaneous Coronary Intervention in Myocardial Infarction Patients: A Systematic Review and Meta-Analysis

  • Evidence-Based Integrative Medicine
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To systematic review the effect of Chinese medicine (CM) on no or slow reflow after percutaneous coronary intervention (PCI) in myocardial infarction (MI) patients.

Methods

The PubMed, EMBASE databases, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, China National Knowledge Infrastructure (CNKI), Chinese BioMedical Literature Database (CBM), Wanfang Knowledge Service Platform (Wanfang Database) and Chinese Scientific Journal Database (VIP) were searched up to December 2017. Randomized controlled trials (RCTs) which evaluated the effect of CM therapies on no or slow reflow after PCI in MI patients were included. The primary outcome was the effect of reperfusion. Secondary outcomes were left ventricular ejection fraction, incidence of major adverse cardiovascular events and adverse effect.

Results

Ten RCTs covering 814 patients were included. Two studies revealed that the incidence of no or slow reflow was less in Shenmai Injection (参麦注射液) group than in the control group measured by thrombolysis in myocardial infarction (TIMI) ⩽ 2 (risk ratio=0.55, 95% confidence interval 0.38 to 0.81, P=0.003, I2=37%). Two studies indicated that Salvianolate Injection showed no additional benefit on no or slow reflow measured by corrected TIMI frame count compared with the conventional treatment (mean difference −4.24, 95% confidence interval −13.03 to 4.54, P=0.34, I2=86%). In addition, Tongxinluo Capsules (通心络胶囊), Danhong Injection (丹红注射液) and Xuesaitong Injection (血塞通注射液) may have the potential to reduce no or slow reflow measured during or after PCI in individual studies.

Conclusions

Current evidence from RCTs are not sufficient to evaluate the effect of CM adjuvant therapies on no or slow reflow after PCI for MI patients. The included studies are limited by small sample size and unclear baseline conditions. Further rigorously designed researches and verification studies with sufficient number of patients are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Benjamin EJ, Blaha MJ, Chiuve SE, Das SR, Deo R, Ferranti SD, et al. Heart disease and stroke statistics—2017 update: A report from the American Heart Association. Circulation 2017;135:e146–603.

    Article  Google Scholar 

  2. Chen WW, Gao RL, Liu LS, Zhu ML, Wang W, Wang YJ, et al. China cardiovascular diseases report 2015: a summary. J Geriatr Cardiol 2017;14:1–10.

    PubMed  PubMed Central  Google Scholar 

  3. Frans VDW. The history of coronary reperfusion. Eur Heart J 2014;35:2510–2515.

    Article  Google Scholar 

  4. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999–3054.

    Article  Google Scholar 

  5. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003;145:42–46.

    Article  Google Scholar 

  6. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009;54:281–292.

    Article  Google Scholar 

  7. Bouleti C, Mewton N, Germain S. The no-reflow phenomenon: State of the art. Arch Cardiovasc Dis 2015;108:661–674.

    Article  Google Scholar 

  8. Abbate A, Kontos MC, Biondi-Zoccai GG. No-reflow: the next challenge in treatment of ST-elevation acute myocardial infarction. Eur Heart J 2008;29:1795–1797.

    Article  CAS  Google Scholar 

  9. Liu HX. Consensus of traditional Chinese medicine specialists on percutaneous coronary intervention (PCI) perioperative myocardial injury. World Chin Med (Chin) 2016;11:377–380.

    Google Scholar 

  10. Tang E, Hou YZ, Mao JY, Wang JY, Zhao ZQ. Effect of complementary treatment of Chinese drugs on myocardial perfusion patients with acute myocardial infarction after coronary intervention: a systematic review. Chin J Integr Tradi West Med (Chin) 2014;34:1425–1431.

    CAS  Google Scholar 

  11. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated march 2011). The Cochrane Collaboration, 2011 available from www.Cochrane-Handbook.Org (accessed 20 Dec 2017).

  12. Jia M, Liu JL, Gai F, Wang YX, Zhou F, Zhang Y. Effect of Danhong Injection combined with nitroglycerin on no-reflow and CRP in PCI treatment for AMI patients. J Hebei Tradit Chin Med Pharmacol (Chin) 2015;30:5–7.

    Google Scholar 

  13. Wang BZ, Zhou CY, Guo ML, Li P, Zhang XZ. Effect of Danhong on myocardial no-reflow after percutaneous coronary intervention in patients with ST-elevation myocardial infarction and its mechanism. Med J Qilu (Chin) 2013;28:250–252.

    Google Scholar 

  14. Yang XZ, Zheng Y, Guo SQ, Li JJ, Shang SZ. Clinical observation on intracoronary injection with Shenmai Injection and Western medicine for no-reflow after percutaneous coronary intervention in patients with acute myocardial infarction. J Tradit Chin Med (Chin) 2014;55:854–857.

    Google Scholar 

  15. Guo S. Research on Shenmai Injection combined with Western medcine in treating acute myocardial infarction. Chin J Mod Drug Appl (Chin) 2014;8:132–134.

    Google Scholar 

  16. Liu Y, Deng B, Xu JH, Li YY, Xu WJ, Jiang JF. Effect of polydanshinolate on myocardial reperfusion after percutaneous coronary interventions in patients. Clin Med China (Chin) 2010;26:121–126.

    Google Scholar 

  17. Zhang XJ, Chen ZM, Huang SE, Zhang QS, Jin L, Deng M. Effect of Salvianolate Injection on myocardial microcirculation in diabetes patients with acute myocardial infarction after percutanous coronary intervention. Zhejiang J Integr Tradit Chin West Med (Chin) 2017;27:27–28.

    Google Scholar 

  18. Zhang HT, Jia ZH, Zhang J, Ye ZK, Tian YQ, Jia X, et al. No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: A randomized double-blind placebo-controlled multicenter clinical trial (ENLEAT trial). Chin Med J 2010;123:2858–2864.

    PubMed  Google Scholar 

  19. Gan LJ, Zhang CH, Zhang M. Effect of intracoronary injection with xuesaitong in treating post-PCI slow-reflow phenomenon in patients with ST-segment elevation myocardial infarction. Chin J Integr Med (Chin) 2010;30:348–351.

    Google Scholar 

  20. Yang J, Fang YM, Li SC, Yu B, Liu SR. The effect of Ligustrazine on myocardium microcirculation perfusion in patients with acute myocardial infarction after emergency percutaneous coronary intervention. J Chin Microcircul (Chin) 2006;10:89–102.

    Google Scholar 

  21. Zheng ZD, Cheng CL, Dong RM, Zhu JM, Zhao CL, Qian XX, et al. Effect of Shuxuetong Injection on cardiac function of AMI patients with no-reflow phenomenon after percutaneous coronary intervention. Chin J Integr Med Cardio Cerebrovas Dis (Chin) 2015;13:1193–1195.

    Google Scholar 

  22. Li L, Huang QF. Effects of Shenmai Injection on acute myocardial ischemia-reperfusion injury in rats. Chin J Pathophysiol (Chin) 2003;19:1472–1475.

    Google Scholar 

  23. Li XD, Yang YJ, Geng YJ, Jin C, Hu FH, Zhao JL, et al. Tongxinluo reduces myocardial no-reflow and ischemia-reperfusion injury by stimulating the phosphorylation of eNOS via the PKA pathway. Am J Physiol Heart Circ Physiol 2010;299:H1255–1261.

    Article  CAS  Google Scholar 

  24. Zhang HT, Yang YJ, Cheng YT, Kang C, Zhao JL, Meng L, et al. Effect of Tongxinluo on miniswine cytokines and myocardial no-reflow in early reperfusion of acute myocardial infarction. Chin J Integr Med Tradit West (Chin) 2009;29:821–824.

    Google Scholar 

  25. Zhang YJ, Wang X. Effect of Salvianolate on rats with ischemia-reperfusion injury. Chin J Gerontol (Chin) 2013;33:5659–5661.

    CAS  Google Scholar 

  26. Yang J, Cui HM, Ren YS, Wu ZG. Danhong Injection in patients with no-reflow/slow-flow following primary PCI of ST-segment elevation myocardial infarction. World J Integr Tradit West Med (Chin) 2015;10:210–225.

    Google Scholar 

  27. Lian JX, Zheng XJ, Tao GF, Qin YM, Tang XM. The protective action of Xuesetong on rats myocardial ischemia. Shaanxi Med J (Chin) 2006;35:1086–1089.

    Google Scholar 

  28. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J 2015;37:1024–1033.

    Article  Google Scholar 

  29. Kaltoft A, Bottcher M, Sand NP, Rehling M, Andersen NT, Zijlstra F, et al. Sestamibi single photon emission computed tomography immediately after primary percutaneous coronary intervention identifies patients at risk for large infarcts. Am Heart J 2006;151:1108–1114.

    Article  Google Scholar 

  30. Durante A, Camici PG. Novel insights into an “old” phenomenon: the no reflow. Int J Cardiol 2015;187:273–280.

    Article  Google Scholar 

  31. Rong J, Xu YZ, Zhang JP. TCM syndrome of patients with coronary heart disease before and after percutaneous coronary intervention. J Tradit Chin Med (Chin) 2012;53:2027–2030.

    Google Scholar 

  32. Zhang JY, Li SC, Li YK, Zhao L, Weng WL, Li LD, et al. Advantages of traditional Chinese medicine in treating myocardial no-reflow after acute myocardial infarction/reperfusion. Chin J New Drugs (Chin) 2015;24:276–280.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China

    Xiao-yu Zhang, Yang Sun, Xin-yu Yang, Jia-yuan Hu, Rui Zheng, Shi-qi Chen, Min Li, Cheng-yu Li, Yin Jiang, Shuo Liu & Hong-cai Shang

  2. School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, 999077, China

    Chen Zhao

  3. Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China

    Yan-wei Xing

  4. Integrative Medicine Institute, Guangzhou Medical University, Guangzhou, 511436, China

    Hong-cai Shang

Authors
  1. Xiao-yu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yang Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xin-yu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jia-yuan Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rui Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shi-qi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Min Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Cheng-yu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yin Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shuo Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Chen Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yan-wei Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hong-cai Shang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Shang HC and Zhang XY defined the research theme. Zhang XY and Sun Y designed the methods, analyzed the data and wrote the initial draft of the paper. Zhang XY, Yang XY and Zheng R interpreted the results. Hu JY, Chen SQ, Li M helped with the literature search. Li CY, Jiang Y, Liu S revised the manuscript. Shang HC, Zhao C and Xing YW refined the idea of the study and gave valuable suggestions. All authors discussed the results and commented on the manuscript.

Corresponding author

Correspondence to Hong-cai Shang.

Additional information

Conflict of Interest

The authors declare no competing financial interests.

Supported by the National Key Research and Development Program of China (No. 2017YFC1700402), the National Natural Science Foundation of China (No. 81725024) and the Fundamental Research Funds for the Central Universities (No. 2018-JYBZZ-XS145)

Electronic Supplementary Material

11655_2019_2703_MOESM1_ESM.doc

Effect of Chinese Medicine on No or Slow Reflow after Percutaneous Coronary Intervention in Myocardial Infarction Patients: A Systematic Review and Meta-Analysis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Xy., Sun, Y., Yang, Xy. et al. Effect of Chinese Medicine on No or Slow Reflow after Percutaneous Coronary Intervention in Myocardial Infarction Patients: A Systematic Review and Meta-Analysis. Chin. J. Integr. Med. 26, 227–234 (2020). https://doi.org/10.1007/s11655-019-2703-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-019-2703-9

Keywords

Search

Navigation